| M | T | W | T | F | S | S | |
|---|---|---|---|---|---|---|---|
 | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
| 8 | 9 | 10 | 11 | 12 | 13 | 14 |
| 15 | 16 | 17 | 18 | 19 | 20 | 21 |
| 22 | 23 | 24 | 25 | 26 | 27 | 28 |
| 29 | 30 | 31 |
NOVOGEN LIMITED (NRT)
Stock Code: NRT
Listing Date: 1994-09-01 00:00:00
Website: http://www.novogen.com
Industry: Pharmaceuticals, Biotechnology & Life Sciences
Principal Activities:
Pharmaceutical research and development and manufacturing and marketing of health supplements.
Address:
140 Wicks Road
NORTH RYDE
NSW 2113
Phone: (02) 9878 0088
Fax: (02) 9878 0055
Executives & Directors
Mr Philip A Johnston, Chairman, Non Exec. Director
Mr Christopher Naughton, Executive Director, Managing Director, CEO
Prof. Alan James Husband, Executive Director
Mr Peter B Simpson, Non Exec. Director
Prof. Paul J Nestel, AO, Non Exec. Director
Mr Geoffrey M Leppinus, Non Exec. Director
Mr David R Seaton, CFO
Mr Ronald L Erratt, Company Secretary
Company Podcasts
Subscribe to current and future audio events for this company by clicking on the podcast icon:
Company ASX Announcements
Company ASX announcements can be viewed on the ASX website.
Announcements from the preceding six months are shown below.
Click here to view this company's details on the ASX site
Company Events
NOVOGEN LIMITED (NRT)
| NV-128 potential activity against cancer stem cells | Tue, 2 Dec 2008 |
| IND filed for triphendiol | Tue, 2 Dec 2008 |
| Appendix 3Y | Tue, 2 Dec 2008 |
| IDMC recommends Marshall Edwards`s OVATURE Trial Continues | Thu, 13 Nov 2008 |
| Appendix 3B | Wed, 5 Nov 2008 |
| Results of Meeting | Mon, 3 Nov 2008 |
| Chairmans Report AGM 2008 | Fri, 31 Oct 2008 |
| Phenoxodiol and NV-128 show potent synergiatic effect | Wed, 29 Oct 2008 |
| Glycotex reports first patient in new study | Wed, 22 Oct 2008 |
| Glycotex Inc announces collaboration | Tue, 21 Oct 2008 |
| Annual Report 2008 | Tue, 7 Oct 2008 |
| Notice of Meeting 2008 | Tue, 7 Oct 2008 |
| Appendix 4E and Annual Report | Thu, 28 Aug 2008 |
| Marshall Edwards to present at conference | Mon, 11 Aug 2008 |
| Notification under S708A(5)(e) of the Corporations Act 2001 | Mon, 4 Aug 2008 |
| Novogen Limited raises A$5.5 million | Thu, 31 Jul 2008 |
| Appendix 3B | Thu, 31 Jul 2008 |
| Change in Shareholding | Fri, 4 Jul 2008 |
| Novogen`s Marshall Edwards joins Russell 3000 index | Fri, 27 Jun 2008 |
| Appendix 3Y | Thu, 26 Jun 2008 |
| Novogen signs Spanish patent licence | Mon, 23 Jun 2008 |
| IDMC recommends Ovature trial continues | Tue, 10 Jun 2008 |
| Triphendiol phase 1 trial results presented at ASCO | Mon, 19 May 2008 |
| Extended accrual time and decreased sample size for Ovature | Mon, 12 May 2008 |
| Newsletter to shareholders - May 2008 | Wed, 7 May 2008 |
| Novogen NV-128 presentation at AACR | Wed, 16 Apr 2008 |
| Triphendiol demonstrates activity against biliary cancers | Mon, 14 Apr 2008 |
| Appendix 3B | Thu, 3 Apr 2008 |
| Novogen cardiovascular drug enters Phase I trial | Wed, 2 Apr 2008 |
| Interview with Christopher Naughton, CEO, Novogen | Wed, 2 Apr 2008 |
| Data reveals triphendiol may aid pancreatic cancer | Wed, 26 Mar 2008 |
| Yale to present data on Novogen`s NV-128 | Tue, 25 Mar 2008 |
| Study demonstrates the safety of Promensil | Tue, 25 Mar 2008 |
| Glycotex completes enrolment in wound healing trial | Thu, 13 Mar 2008 |
| Phenoxodiol highlighted at cancer conference | Tue, 11 Mar 2008 |
| Half Yearly Report and Accounts | Fri, 29 Feb 2008 |
| Novogen`s subsidiary granted third orphan drug status | Wed, 20 Feb 2008 |
| Change in substantial holding | Tue, 5 Feb 2008 |
| Appendix 3Y | Thu, 20 Dec 2007 |
| Response to ASX Query | Wed, 5 Dec 2007 |
| Novogen Limited Audio Stream 230pm today | Wed, 5 Dec 2007 |
| Novogen`s NV-52 may treat Inflammatory Bowel Disease | Tue, 4 Dec 2007 |
| Appendix 3Y | Mon, 26 Nov 2007 |
| NV-52 may treat Inflammatory Bowel Disease | Tue, 13 Nov 2007 |
| European symposium focuses on phenoxodiol | Wed, 31 Oct 2007 |
| Results of Meeting | Mon, 29 Oct 2007 |
| Novogen announces cosmetic collaboration | Fri, 26 Oct 2007 |
| Chairman`s address to shareholders | Fri, 26 Oct 2007 |
| Novogen NV-128 induces novel mode of cell death in cancer ce | Thu, 25 Oct 2007 |
| Yale Cancer Centre sponsors phenoxodiol prostate study | Tue, 23 Oct 2007 |
Please note: This company appears on this website as a result of its listing on the Australian Securities Exchange. Boardroom Radio does not claim any association with any company listed on this site.